The basic concept of glass packaging for gunpowder

  • Detail

The basic concept of pharmaceutical glass packaging and the basic situation of pharmaceutical packaging in China

new pharmaceutical glass packaging:

class I glass molded bottle: it is mainly used to package products such as plasma, albumin, globulin, etc., and the specification is 20ml-100ml

class I glass tube bottle: it is mainly used for packaging freeze-dried biological agents, powder injections, vaccines, genetic engineering drugs and other products. The specification is 3ml-12ml, mainly 2ml-8ml, and the large specification also has 32ml

cartridge: ampoules for injection have been partially replaced in foreign countries for the packaging of high-grade high-volume liquid dosage forms, and they are mainly used in the packaging of insulin injections in China

pre filled syringe: it is mainly used to pack biological drugs such as vaccines and interferons. It is a disposable drug containing injection

introduction to the two major glass packaging enterprises in Europe and America: there is no pure pharmaceutical glass packaging enterprise in the world.

American O-I: the world's largest glass packaging manufacturer. O-I glass packaging involves food, beverages, cosmetics and drugs. Glass packaging accounts for 89% of its business income, and the other 11% is plastic packaging. In 2005, the sales scale of O-I was 707.9 billion US dollars, of which the sales scale of glass packaging was 630billion US dollars

Saint Gobain in France: Saint Gobain's business involves five fields, and the packaging revenue accounts for only 11% of the company's business revenue. The sales scale in 2005 was $479.9 billion, and the scale of glass packaging is smaller. Another of the company's five businesses is flat glass

China's drug packaging has gone through three stages:

era: brown bottles, straw cartons by clicking the "add to header" button, and straight neck ampoules are the main packaging. The drug packaging is bulky and practical

era: greatly affected by the cultural revolution, from the late 1960s to the late 1970s, there was no registered trademark on drug packaging, which was a painful period for drug packaging in China, and the development of drug packaging completely stagnated

since the 1980s: the registered trademark of drugs was restored in the early 1980s, the pharmaceutical packaging industry began to develop healthily, and the packaging materials aluminum-plastic, paper plastic, laser anti-counterfeiting and other composite materials were gradually popularized

on April 29, 2004, China promulgated the "measures for the administration of pharmaceutical packaging materials and containers (Provisional)", which divides pharmaceutical packaging materials into three categories: I, II and III:

category I refers to the materials and containers for pharmaceutical packaging that are in direct contact with drugs and used directly

class II refers to the materials and containers for drug packaging that are in direct contact with drugs but easy to clean. In the actual use process, they need to be cleaned and can be disinfected and sterilized

class III refers to other materials and containers for drug packaging that may directly affect the quality of drugs other than class I and II

at present, the main pharmaceutical packaging materials mainly include the following categories:

rubber packaging materials: mainly in the form of plugs and gaskets of containers, which are divided into natural rubber and butyl rubber. Natural rubber has been listed and eliminated by the government because of its poor sealing property and the need to be supplemented by sealing wax, and its chemical properties are unstable; Butyl rubber has excellent sealing performance, replacing natural rubber stopper as injection packaging

metal packaging materials: mainly used for the aluminum cap of powder injection packaging, the bottle body of paste and aerosol, and the medicinal aluminum foil of aluminum plastic blister packaging. Aluminum plastic composite cover has been accepted by more and more markets because of its convenient opening, safe and hygienic use. Aluminum aluminum packaging developed in recent years is a new packaging material with strong barrier, which can prolong the shelf life of drugs, especially for drugs with poor chemical stability

glass packaging materials: widely used in injection, powder injection, biological drugs, blood products, freeze-drying agents, oral liquids and other fields. Glass has good chemical stability, which is not affected by the atmosphere and is not decomposed by solid or liquid substances with different chemical compositions. By changing the chemical composition of glass, the chemical properties and radiation resistance of glass can be adjusted. Moreover, glass has transparent, beautiful, low price, recyclable and other properties, which will not cause environmental problems

composite packaging materials: mainly including plastic bottles for oral solids, which are still the first choice for customers, plastic bottles for liquids, etc., which are mostly made of high-density polyethylene or polypropylene, polyester materials

2. Shandong Pharmaceutical glass, the largest pharmaceutical glass packaging enterprise in China, was founded in 1970. Starting from antibiotic glass packaging, Shandong Pharmaceutical glass adopts the strategy of low price to seize market share and continuous technological innovation. The market share of molded antibiotic bottles reaches 79%, and it is the largest pharmaceutical glass packaging manufacturer in China

at present, the company can produce six series of more than 400 products, such as molded antibiotic bottles, ampoules, controlled bottles, infusion bottles, glass tubes, brown bottles, as well as butyl rubber plugs, aluminum plastic caps, plastic bottles and other products, and has recently developed neutral borosilicate class I glass, becoming the first pharmaceutical glass packaging enterprise in China and the fifth in the world that can produce class I glass

the total share capital of the company is 222million, with 155million non tradable shares. The controlling shareholder Yiyuan County public assets management committee holds 24.86% of the company's equity, non tradable shareholders hold 69.51% of the company's equity, and other non tradable shareholders hold 5.63% of the company's equity

the company's main raw material soda ash accounts for about 10% of the production cost, and the main energy consumption coal accounts for about 18% of the production cost. In 2004, the production cost increased by more than 30 million due to the rising price of soda ash and the rising price of coal. At the same time, the government originally planned to fully replace the natural rubber plug on December 31, 2004. The antibiotic plug was postponed to June 30, 2005, and the infusion plug was postponed to December 31, 2005, which greatly affected the effectiveness of fund-raising, Even so, the company still absorbed the rising costs through technological innovation and maintained a steady increase in profits

3. Taking the lead in scale and cost, membrane anti bottle is a cash flow business. Antibiotic powder injection accounts for an absolute sales share in China's Injection Market. The company has worked hard in the field of pharmaceutical glass packaging, forming a strong technical advantage. The market share of membrane anti bottle is 79%, the production efficiency is more than 70% higher than that of peers, and the gross profit margin is more than 10 points higher than that of competitors. Relying on technological innovation, The company's market competition strategy is to continuously reduce the price of common specification mold resistant bottles, launch new products with high gross yield to replace the old varieties with a one-step advantage, and gradually force competitors out of the market. It is expected that urban consumption in China's antibiotic market will shrink and rural consumption will grow steadily. As the main manufacturer of antibiotic molded bottles, the company will have a stable scale of membrane anti bottle in the future, and the transfer to Baotou industry may effectively reduce costs. Membrane anti bottle has become a stable cash flow business of the company

the giant in the small antibiotic powder injection industry wins customers with scale and cost

the penicillin powder injection industry, which accounts for 70% of the antibiotic powder injection market share, shows a high degree of industrial concentration, and% of the production capacity is concentrated in four major manufacturers: Harbin pharmaceutical, Shijiazhuang Pharmaceutical, North China Pharmaceutical and Lukang Pharmaceutical. Among them, North China Pharmaceutical has an annual output of about 1.2 billion penicillin powder injections, which are mainly packaged in controlled bottles, The remaining three companies use about 4billion McAbs every year, and the scale of the company has reached 8.7 billion McAbs, which is capable of covering downstream customers. We believe that scale has become a bottleneck in the competition of the upstream packaging industry

in recent years, the sales scale of the company's top five sales customers has been stable at 1 The heavyweight manufacturers of antibiotic powder injection, Harbin pharmaceutical, Northeast Pharmaceutical, Shiyao, Qilu, Shanghai Xianfeng and Shanghai Xinya, are basically under the company's banner. Although pharmaceutical enterprises are constantly discussing entering the molded bottle industry, the price of Shandong Pharmaceutical Glass mold anti bottle delivered to the warehouse of pharmaceutical enterprises is lower than the production cost of pharmaceutical enterprises entering the mold anti bottle industry, which also makes pharmaceutical enterprises constantly give up entering the mold anti bottle industry with a sales scale of only more than 500 million

in addition, due to the small proportion (%) of pharmaceutical glass bottles in the value of drugs, the first consideration for downstream enterprises to choose glass bottles is the stability of the quality of glass bottles in the process of large-scale continuous filling of drugs and the adaptability of their filling equipment. The company has established a long-term stable cooperative relationship with nearly 800 customers, and the quality of mold resistant bottles produced has fully adapted to the requirements of downstream manufacturers on the mechanical strength, specifications and other aspects of bottles, μ= Friction coefficient f = scale factor, which makes the company's customers have good continuity and stability

the gross profit margin is more than 10 points higher than that of competitors, and the company wins profits with technical advantages

in recent years, the company has continuously invested in technological transformation, and has independently developed domestic leading technologies such as light-weight thin-wall mold anti bottle production technology, high white material mold anti bottle production technology, servo parallel cutting and feeding technology, electric servo material distribution technology, small mouth pressure blowing technology, and so on. The transformation of purchased production equipment not only improves the product quality, Moreover, the production efficiency has been greatly improved. By 2003 and 2004, the production efficiency of a mold anti bottle production line has been more than 70% higher than that of its peers, which makes the gross profit margin of the company's mold anti bottle much higher than the industry average gross profit margin by more than ten points (in 2005, the company's mold anti bottle gross profit margin was 41%, and the industry average gross profit margin was about 30%). The sales price of some products is close to the cost price of peers, and the company relies entirely on technical advantages to win profits

in 2004, when the cost increased by more than 30 million, the production efficiency was improved through technological optimization. The company digested the cost of 25million, and the gross profit margin of mold anti bottle continued to maintain a high level, reflecting the company's strong internal management, technical ability and competitiveness

adjust the product structure and stabilize the leading position in the industry

at present, the company has nearly 300 kinds of mold resistance bottle specifications from 5ml-100ml, while peer enterprises can only produce more than 10 kinds of specifications at most. By constantly launching new products with high gross yield and upgrading, there may also be differences, reducing the price of the existing specifications of the competitors, suppressing the competitors, and gradually forcing the competitors out of the market. The company's market strategy has achieved absolute results, and its leading position in the industry has been constantly stable

in line with the trend of large-scale standardization of mold resist bottles, the company has used the experience accumulated in the glass packaging industry for 30 years to continuously develop new mold resist bottles, take the lead in the industry in lightweight, high-grade and large-scale standardization, lead the industry consumption trend, and win high-end customers of Pfizer from Saint Gobain in France

the transfer of membrane anti bottle to Baotou industry will effectively reduce costs and become a cash flow business

due to China's unique clinical promotion and sales mode of prescription drugs, the sales of oral antibiotics in urban hospitals are swollen, and antibiotic powder injections are mainly "exaggerated" in terms of money. The water content of sales is not very large, but with the gradual rational use of drugs, the consumption of antibiotic injections in urban hospitals in China will shrink in the future, Rural areas have become the main force in the increase of antibiotic consumption. As the main manufacturer of membrane anti bottle, the scale of membrane anti bottle will be stable in the future

Copyright © 2011 JIN SHI